Publications
5808 Results
- Journal / Conference
- Bladder Cancer Oct 23;10(3):199-213
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID39493817
- PMC
- PMC11530036
- Study Number(s)
- S1806
Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer
- Journal / Conference
- ESH-iCMLf 26th Annual John Goldman CML meeting (Sept 27-29, 2024, Prague, Czech Republic), accepted, oral
- Year
- 2024
- Research Committee(s)
- Leukemia
- Study Number(s)
- S1712
A Randomized Trial of the Addition of Ruxolitinib to BCR::ABL Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia with Molecular Evidence of Disease (SWOG Trial S1712)
- Journal / Conference
- ISHL (October 26-28, 2024 Cologne, Germany), oral
- Year
- 2024
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma
- Journal / Conference
- ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster abstract 1530. Blood (2024) 144 (Suppl 1): 1530. doi: 10.1182/blood-2024-201213
- Year
- 2024
- Research Committee(s)
- Leukemia
4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)
- Journal / Conference
- ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
- Year
- 2024
- Research Committee(s)
- Lymphoma
Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in minimal residual disease (MRD)-negative first complete remission (CR): Initial report from ECOG-ACRIN EA4151
- Journal / Conference
- ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
- Year
- 2024
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/A052101
Trial in Progress – Alliance A052101: A randomized phase 3 trial of continuous vs. intermittent maintenance therapy with zanubrutinib as upfront treatment in older patients with mantle cell lymphoma
- Journal / Conference
- ABRCMS 2024 Graduate Symposium (Nov. 13-16 in Pittsburgh, PA), poster
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
Outcome and Treatment Toxicity at Community versus Academic Sites for Patients with Rare Cancers on Immune Checkpoint Inhibitors (NCI/SWOG S1609)
- Journal / Conference
- Journal of the National Cancer Institute
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID39180477
- PMC
- PMC11630502
- Study Number(s)
- CTSU/C80702
Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
- Journal / Conference
- Lancet Gastroenterol Hepatol, 9(1), 15
- Year
- 2024
- Research Committee(s)
- Palliative Care
- Study Number(s)
- S1316
Management of malignant bowel obstruction - Authors‘ reply
- Journal / Conference
- medRxiv.
- Year
- 2024
- Research Committee(s)
- Prevention, Screening, and and Surveillance